Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

PURPOSE: To determine the maximum-tolerated dose (MTD) and assess safety, pharmacokinetics, pharmacodynamics, and evidence of antitumor activity of RO4929097, a gamma secretase inhibitor of Notch signaling in patients with advanced solid malignancies. PATIENTS AND METHODS: Patients received escalati...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Tolcher, Anthony W., Messersmith, Wells A., Mikulski, Stanislaw M., Papadopoulos, Kyriakos P., Kwak, Eunice L., Gibbon, Darlene G., Patnaik, Amita, Falchook, Gerald S., Dasari, Arvind, Shapiro, Geoffrey I., Boylan, John F., Xu, Zhi-Xin, Wang, Ka, Koehler, Astrid, Song, James, Middleton, Steven A., Deutsch, Jonathan, DeMario, Mark, Kurzrock, Razelle, Wheler, Jennifer J.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2012
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5950496/
https://ncbi.nlm.nih.gov/pubmed/22529266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.36.8282
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars